Symbols

RNAM

Avidity Biosciences·NASDAQ

--(--)

RNAM Profile

Avidity Biosciences, Inc.

A clinical stage biopharmaceutical company specializing in antibody oligonucleotide coupling(AOC)technology and focusing on rare diseases and muscle diseases

Industry

Biological Technology

Established Date

11/13/2012

Listing Date

06/12/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

511

Fiscal Year Ends

12-31

Website

www.aviditybiosciences.com

Security Type

Common stock

Office address

3020 Callan Road, San Diego, CA 92121

Business

Introduction

Avidity Biosciences, Inc., was incorporated on November 13, 2012 under the laws of the State of Delaware. The company is working on a new class of RNA therapies called antibody oligonucleotide conjugates (AOCs). Its proprietary AOC platform combines the specificity of monoclonal antibodies with the precision of RNA therapies to target previously incurable diseases. Avidity's pipeline includes three clinical development programs: delpacibart zotadirsen for Duchenne muscular dystrophy, delpacibart etedesiran for type 1 myotonic dystrophy, and delpacibart braxlosiran for facioscapulobrachial muscular dystrophy. All of these investigational therapies have received orphan designation and fast track status from regulatory agencies. In November 2025, Avidity announced its del-zota managed access program in the United States, providing access to eligible patients through an authorized treatment regimen.